ArticleDiscover oncology2026
FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a highly aggressive malignancy with limited treatment options and poor prognosis. FK506-binding protein 10 (FKBP10), a member of the FKBP family, has been associated with the progression of various cancers, but its role in HCC remains unclear. METHODOLOGY: In this study, we performed a comprehensive multi-omics analysis integrating bulk and single-cell transcriptomic data to investigate the expression pattern, clinical relevance, immune landscape, and functional roles of FKBP10 in HCC. Public datasets including TCGA, CPTAC, GEPIA, TIMER, and TISIDB were used for transcriptomic and clinical correlation analyses.
resultsOur findings showed that gene enrichment and gene set enrichment analysis (GSEA) revealed that FKBP10 is involved in extracellular matrix (ECM) organization and epithelial-mesenchymal transition (EMT). Single-cell and spatial transcriptomics identified FKBP10 as a specific marker of cancer-associated fibroblasts (CAFs), which displayed strong intercellular signaling through collagen and laminin pathways. High FKBP10 expression was significantly associated with advanced tumor grade, lymph node metastasis, and HBV infection, and served as an independent predictor of poor overall and disease-free survival. Furthermore, FKBP10 expression correlated with an immunosuppressive tumor microenvironment and elevated expression of immune checkpoint genes. Drug sensitivity profiling indicated that tumors with high FKBP10 expression may be more responsive to PI3K-mTOR and AKT inhibitors.
conclusionThese findings suggest that FKBP10 plays a multifaceted role in HCC progression and may serve as both a prognostic biomarker and a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.